PMP22 and Charcot-Marie-Tooth disease type 1A: In a recent study by Boutary et al., 3-weekly intravenous injection of PMP22 siRNA nanoparticles improved behavioural and electrophysiological parameters in two mouse models of CMT1A in which they were able to demonstrate penetration of nanoparticles into Schwann cells [6].